Principaux documents

Voir toute la documentation

581325-U

Ascentis^® C18 (5 µm) HPLC Columns

Name: Ascentis<SUP>&#174;</SUP> C18 (5 µm) HPLC Columns
Brand: SUPELCO

L × I.D. 25 cm × 4.6 mm, HPLC Column

Synonyme(s) :

Ascentis RP18 HPLC Column

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

UNSPSC Code:

41115700

eCl@ss:

32110501

NACRES:

SB.52

L × i.d.:

25 cm × 4.6 mm

Particle size:

5 μm

Matrix active group:

C18 (RP18), C18 (octadecyl) phase

Pore size:

100 Å

Matrix:

fully porous particle, silica gel high purity, spherical

Service technique

Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.

Laissez-nous vous aider

Propriétés

Nom du produit

Colonne HPLC Ascentis^® C18, 5 μm particle size, L × I.D. 25 cm × 4.6 mm

material

stainless steel column

Quality Segment

100

agency

suitable for USP L1 (Similar to Phenomenex Luna C18)

product line

Ascentis^®

feature

endcapped

manufacturer/tradename

Ascentis^®

packaging

1 ea of

extent of labeling

25% Carbon loading

parameter

≤70 °C temp. range, 400 bar pressure (5801 psi)

technique(s)

HPLC: suitable, LC/MS: suitable

L × I.D.

25 cm × 4.6 mm

surface area

450 m²/g

surface coverage

3.7 μmol/m²

impurities

<5 ppm metals

matrix

fully porous particle, silica gel high purity, spherical

matrix active group

C18 (RP18), C18 (octadecyl) phase

particle size

5 μm

pore size

100 Å

operating pH range

2-8

application(s)

food and beverages

separation technique

reversed phase

Description

General description

Ascentis C18 est une colonne de première intention pour HPLC, extrêmement stable et fiable, qui donne des pics de forme symétrique et une excellente rétention, y compris pour des composés difficiles.

Application

Identification of recombinant human insulin and biosynthetic insulin analogues by multiplexed targeted unlabeled mass spectrometry of proteotypic tryptic peptides.: This study utilized the Ascentis^® C18 HPLC column for the separation of proteotypic tryptic peptides in the identification of insulin analogues, highlighting its application in targeted mass spectrometry for proteomic analysis (Qasem RJ et al., 2019).

Development and validation of a novel stability-indicating HPLC method for the simultaneous assay of betamethasone-17-valerate, fusidic acid, potassium sorbate, methylparaben and propylparaben in a topical cream preparation.: This research developed and validated an HPLC method using the Ascentis^® C18 HPLC column for the simultaneous assay of multiple compounds, demonstrating its robustness in stability testing of pharmaceutical formulations (Byrne J et al., 2014).

HPLC-DAD and HPLC-ESI-MS/MS methods for metabolite profiling of propolis extracts.: The study employed the Ascentis^® C18 HPLC column for metabolite profiling of propolis extracts using HPLC-DAD and HPLC-ESI-MS/MS, showcasing its effectiveness in complex natural product analysis (Pellati F et al., 2011).

Practical comparison of 2.7 microm fused-core silica particles and porous sub-2 microm particles for fast separations in pharmaceutical process development.: This article compared different HPLC column technologies, including the Ascentis^® C18, highlighting its performance in fast separations critical for pharmaceutical process development (Abrahim A et al., 2010).

Features and Benefits

Excellente rétention
Forme symétrique du pic
Forte reproducibilité
Compatibilité totale LC-MS

Other Notes

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

Still not finding the right product?

Explore all of our products under Colonne HPLC Ascentis^® C18

Classe de stockage

11 - Combustible Solids

wgk

nwg

flash_point_f

Not applicable

flash_point_c